New radiation method aims to ease gut pain for cancer patients

NCT ID NCT06778408

Recruiting now Symptom relief Sponsor: University of Vermont Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way of giving palliative radiation (HART) to people with metastatic cancer. The goal is to see if it causes fewer stomach and bowel side effects than standard radiation. About 103 adults with cancer that has spread will receive HART to bones or soft tissues in the chest, belly, or pelvis. Researchers will track side effects and quality of life for four weeks after treatment starts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hybrid Palliative Radiation Therapy (HART)
What this could lead to: If successful, HART could become a standard way to deliver palliative radiation with fewer gut-related side effects, improving quality of life for people with metastatic cancer.
What could go wrong: This is a small, single-center phase II trial without a control group, so results may not be widely applicable. The technique may not reduce toxicity as hoped, or other side effects could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER (DIFFERENT SOLID TUMOUR TYPES) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER (DIFFERENT SOLID TUMOUR TYPES) PALLIATIVE RADIOTHERAPY

Contacts and locations

Locations

University of Vermont Medical Center
RECRUITING

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.